Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 8/20 | 0.57 |
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.53 |
| ▸ | MAG | P20916 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30653688 | 1.00 | SELP (0.57) | SELPSIGLEC7MAG | |
| SCHEMBL30654069 | 1.00 | SELP (0.57) | SELPSIGLEC7MAG | |
| SCHEMBL30651807 | 1.00 | SELP (0.57) | SELPSIGLEC7MAG | |
| SCHEMBL30652768 | 1.00 | SELP (0.57) | SELPSIGLEC7MAG | |
| SCHEMBL30653672 | 1.00 | SELP (0.57) | SELPSIGLEC7MAG | |
| SCHEMBL30650235 | 0.99 | SELP (0.57) | SELPSIGLEC7MAG | |
| SCHEMBL30655188 | 0.99 | SELP (0.57) | SELPSIGLEC7MAG | |
| SCHEMBL30913852 | 0.96 | SIGLEC7 (0.59) | SELPSIGLEC7MAG | |
| SCHEMBL16449748 | 0.96 | SIGLEC7 (0.59) | SELPSIGLEC7MAG | |
| SCHEMBL30739464 | 0.96 | SIGLEC7 (0.59) | SELPSIGLEC7MAG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-118924841-A | Application of polygonatum odoratum extract in preparation of medicine for improving type 2 diabetes | 浙江树人学院 | 2024-11-12 | — | — | CN | disclosed |
| WO-2023220387-A2 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20170121360-A1 | APPARATUS AND METHOD FOR OBTAINING GLYCOGLYCEROLIPIDS AND GLYCOSPHINGOLIPIDS FROM LIPID PHASES | GEA WESTFALIA SEPARATOR GROUP GMBH (DE) | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | SELP 158/4885SIGLEC7 692/4885MAG 918/4885 |
| US-20170121360-A1 | APPARATUS AND METHOD FOR OBTAINING GLYCOGLYCEROLIPIDS AND GLYCOSPHINGOLIPIDS FROM LIPID PHASES | AGL, LIPA, MGLL | SELP 1115/4885SIGLEC7 93/4885MAG 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.